» Articles » PMID: 32903408

Lysine Acetyltransferase Inhibitors From Natural Sources

Overview
Journal Front Pharmacol
Date 2020 Sep 9
PMID 32903408
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Acetylation of histone and non-histone protein lysine residues has been widely described as a critical modulator of several cell functions in humans. Lysine acetyltransferases (KATs) catalyse the transfer of acetyl groups on substrate proteins and are involved in multiple physiological processes such as cell signalling, metabolism, gene regulation, and apoptosis. Given the pivotal role of acetylation, the alteration of KATs enzymatic activity has been clearly linked to various cellular dysfunctions leading to several inflammatory, metabolic, neurological, and cancer diseases. Hence, the use KAT inhibitors (KATi) has been suggested as a potentially successful strategy to reverse or prevent these conditions. To date, only a few KATi have proven to be potential drug candidates, and there is still a keen interest in designing molecules showing drug-like properties from both pharmacodynamics and pharmacokinetics point of view. Increasing literature evidence has been highlighting natural compounds as a wide source of molecular scaffolds for developing therapeutic agents, including KATi. In fact, several polyphenols, catechins, quinones, and peptides obtained from natural sources (including nuts, oils, root extracts, and fungi metabolites) have been described as promising KATi. Here we summarize the features of this class of compounds, describing their modes of action, structure-activity relationships and (semi)-synthetic derivatives, with the aim of assisting the development of novel more potent, isoform selective and drug-like KATi.

Citing Articles

Defining proteoform-specific interactions for drug targeting in a native cell signalling environment.

Lutomski C, Bennett J, El-Baba T, Wu D, Hinkle J, Burnap S Nat Chem. 2025; 17(2):204-214.

PMID: 39806141 PMC: 11794133. DOI: 10.1038/s41557-024-01711-w.


ERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B.

Olbromski M, Mrozowska M, Smolarz B, Romanowicz H, Rusak A, Piotrowska A Sci Rep. 2024; 14(1):26935.

PMID: 39505971 PMC: 11541733. DOI: 10.1038/s41598-024-78432-0.


Activation and inhibition of sirtuins: From bench to bedside.

Fiorentino F, Fabbrizi E, Mai A, Rotili D Med Res Rev. 2024; 45(2):484-560.

PMID: 39215785 PMC: 11796339. DOI: 10.1002/med.22076.


Acetylation and Phosphorylation in the Regulation of Hypoxia-Inducible Factor Activities: Additional Options to Modulate Adaptations to Changes in Oxygen Levels.

Minisini M, Cricchi E, Brancolini C Life (Basel). 2024; 14(1).

PMID: 38276269 PMC: 10821055. DOI: 10.3390/life14010020.


Polyherbal and Multimodal Treatments: Kaempferol- and Quercetin-Rich Herbs Alleviate Symptoms of Alzheimer's Disease.

Alexander C, Parsaee A, Vasefi M Biology (Basel). 2023; 12(11).

PMID: 37998052 PMC: 10669725. DOI: 10.3390/biology12111453.


References
1.
Carafa V, Rotili D, Forgione M, Cuomo F, Serretiello E, Hailu G . Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics. 2016; 8:61. PMC: 4879741. DOI: 10.1186/s13148-016-0224-3. View

2.
Vasudevarao M, Mizar P, Kumari S, Mandal S, Siddhanta S, Swamy M . Naphthoquinone-mediated inhibition of lysine acetyltransferase KAT3B/p300, basis for non-toxic inhibitor synthesis. J Biol Chem. 2014; 289(11):7702-17. PMC: 3953281. DOI: 10.1074/jbc.M113.486522. View

3.
Ghizzoni M, Wu J, Gao T, Haisma H, Dekker F, Zheng Y . 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. Eur J Med Chem. 2011; 47(1):337-44. PMC: 3399519. DOI: 10.1016/j.ejmech.2011.11.001. View

4.
Fiorentino F, Mai A, Rotili D . Lysine acetyltransferase inhibitors: structure-activity relationships and potential therapeutic implications. Future Med Chem. 2018; 10(9):1067-1091. DOI: 10.4155/fmc-2017-0244. View

5.
Tomaselli D, Lucidi A, Rotili D, Mai A . Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev. 2019; 40(1):190-244. PMC: 6917854. DOI: 10.1002/med.21600. View